Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea

American Journal of Hematology

Volumn 84, Issue 8, 2009, Pages 529-531

  Olnes, Matthew ^a   Chi, Amy ^a   Haney, Carissa ^a   May, Rose ^a   Minniti, Caterina ^a   James VI, Taylor ^a   Kato, Gregory J ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; HEMOGLOBIN F; HYDROXYUREA;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMOLYSIS; HUMAN; LUNG ARTERY PRESSURE; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TRICUSPID VALVE REGURGITATION;

EID: 67749114687     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21446     Document Type: Article

References (16)

1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895. (Pubitemid 38252536)
2. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: A longitudinal study. Br J Haematol 2006;134:109-115.
3. De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008;83:19-25.
4. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651. (Pubitemid 37430269)
7. Kato GJ, McGowan VR, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood 2006;107:2279-2285.
8. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006;296:310-318. (Pubitemid 44079315)
9. Rodgers GP, Dover GJ, Noguchi CT, et al. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990;322:1037-1045. (Pubitemid 20146662)
10. Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004;117:665-669. (Pubitemid 40288173)
11. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol 2009;144:736-741.
12. Lapouméroulie C, Benkerrou M, Odièvre MH, et al. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. Haematologica 2005;90:401-403.
13. Brun M, Bourdoulous S, Couraud PO, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J 2003;3:215-226. (Pubitemid 37160977)
14. Cokic VP, Andric SA, Stojilkovic SS, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2008;111:1117-1123.
15. Cokic VP, Beleslin-Cokic BB, Tomic M, et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006;108:184-191. (Pubitemid 43990627)
16. Huang J, Kim-Shapiro DB, King SB. Catalase-mediated nitric oxide formation from hydroxyurea. J Med Chem 2004;47:3495-3501. (Pubitemid 38822011)